Soft Tissue Infections
📧 Sign up to get email alerts when something new happens for Soft Tissue Infections.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-06EMA Authorised: Tenkasi (previously Orbactiv) (oritavancin (diphosphate)) — Menarini International Operations Luxembourg S.A.
EMA has authorised Tenkasi (oritavancin diphosphate) for soft tissue infections and bacterial skin diseases, expanding therapeutic options.
-
EMA approval · 2026-02-23EMA Authorised: Emblaveo (avibactam;aztreonam) — Pfizer Europe MA EEIG
The EMA authorised Emblaveo (avibactam/aztreonam) for treating certain Gram-negative bacterial infections, including urinary tract infection…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections.
A clinical trial update examining delafloxacin plasma and tissue concentrations in patients with soft tissue, mediastinitis, and bone/joint …
-
EMA approval · 2025-09-26EMA Authorised: Tigecycline Accord (tigecycline) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Tigecycline Accord (tigecycline) for use by Accord Healthcare S.L.U. for soft tissue infections, in…
-
EMA approval · 2025-03-20EMA Authorised: Sivextro (tedizolid) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Sivextro (tedizolid) by Merck Sharp & Dohme B.V. for the treatment of soft tissue infections and ba…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2023-05-03Clinical Trial Update: Dalbavancin Outpatient Pilot [Phase 4]
A Phase 4 outpatient pilot trial of dalbavancin was withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-04-23Clinical Trial Update: Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).
A Karolinska Institutet-led clinical trial applying systems medicine to necrotizing soft tissue infections has completed.
-
CLINICAL_TRIALS trial_result · 2016-07-25Clinical Trial Update: Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections [Phase 4]
Phase 4 trial update for daptomycin in patients with renal insufficiency and soft tissue infections, including complicated skin and skin str…
-
CLINICAL_TRIALS trial_result · 2015-05-07Clinical Trial Update: Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection [NA]
Clinical trial update for a placebo-controlled study of antibiotic treatment in soft tissue infections; the study status is completed.
-
EMA withdrawal · 2010-09-22EMA Refused: Zeftera (previously Zevtera) (ceftobiprole medocaril) — Janssen-Cilag International NV
The EMA refused approval for Zeftera (ceftobiprole medocaril) from Janssen-Cilag International NV for skin and soft tissue infections, with …
-
CLINICAL_TRIALS trial_result · 2010-09-14Clinical Trial Update: Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections [Phase 2]
A completed Phase 2 trial evaluating the safety and efficacy of daptomycin for complicated skin and skin-structure infections (soft tissue i…
-
EMA withdrawal · 2009-10-23EMA Application withdrawn: Mersarex — Arpida A/S
The EMA status shows withdrawal of the Mersarex application by Arpida A/S for skin infections and soft tissue infections.
-
EMA withdrawal · 2009-08-25EMA Application withdrawn: Ramvocid — Targanta Netherlands B.V.
The EMA withdrew the Ramvocid application by Targanta Netherlands B.V. for Gram-positive bacterial infections, skin diseases, and soft tissu…
-
EMA withdrawal · 2008-10-24EMA Application withdrawn: Vibativ (telavancin) — Astellas Pharma Europe B. V.
EMA withdrew the application for Vibativ (telavancin) by Astellas Pharma Europe B. V.; therapeutic areas include skin infections and staphyl…
-
EMA withdrawal · 2008-09-10EMA Application withdrawn: Exulett — Pfizer Limited
EMA reports withdrawal of the Exulett application by Pfizer Limited for skin and soft tissue infections and staphylococcal infections.
-
EMA withdrawal · 2007-07-26EMA Application withdrawn: Garenoxacin mesylate — Schering-Plough Europe
The EMA application for garenoxacin mesylate by Schering-Plough Europe was withdrawn.